|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM027103455 |
| 003 |
DE-627 |
| 005 |
20231221102841.0 |
| 007 |
tu |
| 008 |
231221s1989 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed24n0091.xml
|
| 035 |
|
|
|a (DE-627)NLM027103455
|
| 035 |
|
|
|a (NLM)2729017
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Asano, H
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Treatment of chlamydial urethritis--studies on clinical effects of ofloxacin
|
| 264 |
|
1 |
|c 1989
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 10.07.1989
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Clinical effects of ofloxacin (OFLX) in the treatment of the patients with chlamydial urethritis was studied. OFLX was administered at a dose of 200 mg, three times daily (600 mg) for 14 days. In all of the 26 patients with chlamydial urethritis, C. trachomatis was eliminated in 7 to 14 days after the start of administration. The subjective clinical symptoms such as pain on urination and abnormal urethral feeling was disappeared in all cases within 7 days after the administration. The objective clinical symptoms, urethral discharge, polymorphonuclear leukocyte (PMNL) in urethral discharge and PMNL in first urine were improved in 94, 68, 91% respectively on 14 days after the administration. Overall clinical efficacy rate of OFLX on 7 days, 14 days and 21 days after the administration in this study was 63, 82, 91% respectively. Whereas subjective symptoms of side effects were noted in 2 patients (7.6%), any additional medical care was needed in none of them. Because of the marked improvement of clinical symptoms and the safety administration, OFLX could be the first regimen to be chosen for the treatment of the patients with chlamydial urethritis
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Ofloxacin
|2 NLM
|
| 650 |
|
7 |
|a A4P49JAZ9H
|2 NLM
|
| 700 |
1 |
|
|a Hibi, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ohshima, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kinukawa, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Matuura, O
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Takeuchi, N
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hattori, R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hasegawa, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fujita, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Matsui, M
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 35(1989), 1 vom: 15. Jan., Seite 191-7
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:35
|g year:1989
|g number:1
|g day:15
|g month:01
|g pages:191-7
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 1989
|e 1
|b 15
|c 01
|h 191-7
|